---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-087031"
form_type: "8-K"
ticker: "EWTX"
cik: "0001710072"
company_name: "Edgewise Therapeutics, Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T11:03:36.109192+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Edgewise Therapeutics Q2 2024 net loss $31.5M; cash $511.8M; EDG-7500 Phase 1 complete

## Summary
- Net loss of $31.5M ($0.34 per share) vs $28.5M in prior quarter; no product revenue.
- Cash and marketable securities $511.8M as of June 30, 2024.
- Completed Phase 1 SAD/MAD trial of EDG-7500 in healthy volunteers; Phase 2 CIRRUS-HCM enrolling.
- Sevasemten: CANYON Phase 2 data in Becker expected Q4 2024; GRAND CANYON pivotal cohort ongoing.
- LYNX Phase 2 in Duchenne data expected Q4 2024; Phase 3 planned H1 2025.

## SEC filing metadata
- accession: 0001104659-24-087031
- form_type: 8-K
- ticker: EWTX
- cik: 0001710072
- company_name: Edgewise Therapeutics, Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710072/000110465924087031/0001104659-24-087031-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710072/000110465924087031/tm2420690d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-087031
- JSON: https://secwatch.observer/filing/0001104659-24-087031.json
- Plain text: https://secwatch.observer/filing/0001104659-24-087031.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.